OUR TEAM

……….

Kenny Green

Kenny Green

Founder View Details
Ehud Helft

Ehud Helft

Managing Partner View Details
Gavriel Frohwein

Gavriel Frohwein

Senior Market Intelligence Executive View Details
Danny Saks

Danny Saks

Director of Biotech View Details
Kenny Green

Kenny Green

Founder

Kenny is the co-founder of GK and has over 15 years experience in crafting compelling investor communications strategies. He has led the investor relations strategy of many leading US listed Israeli companies. Prior to GK, he was an equity research analyst at leading international banks based in London. Kenny has a Masters in Management from Cambridge University, England.

Ehud Helft

Ehud Helft

Managing Partner

Ehud has over 15 years experience in executing customized investor relations programs for many Tel-Aviv and US listed companies. In particular, he has experience with strategising investor relations programs for companies embarking on IPOs. He was formally an equity research analyst and most recently Head of Israel Research at Credit Suisse. Ehud has an MBA from IESE, Barcelona.

Gavriel Frohwein

Gavriel Frohwein

Senior Market Intelligence Executive

Gavriel is responsible for contacts with the buy-side and sell side, with a broad network and close relations with investors and analysts. He has close to a decade of Wall Street experience. He was formerly the marketing director of Leadsco, Canada, aiding Financial Advisors in expanding their client base. Gavriel has a Bachelor of Business Commerce from Ryerson University, Toronto, Canada.

Danny Saks

Danny Saks

Director of Biotech

Danny has extensive background with leading large US IR agencies. He was previously Managing Partner, specializing in life science companies, at The Financial Relations Board, the largest IR agency in the United States. He co-founded the Biotechnology/Pharmaceutical Industry Group of the National Investor Relations Institute. He also has key experience came from executive in-house IR positions in Israel at Taro Pharmaceuticals and at Abraxis BioScience in the US, as well as at two US medical technology startups.